Liver Research Unit, Medica Sur Clinic and Foundation, Mexico City, Mexico.
Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.
Hepatol Int. 2024 Oct;18(Suppl 2):884-896. doi: 10.1007/s12072-024-10662-w. Epub 2024 Jul 25.
Metabolic dysfunction associated fatty liver disease (MAFLD) is an increasing public health problem, affecting one third of the global population. Contrary to conventional wisdom, MAFLD is not exclusive to obese or overweight individuals. Epidemiological studies have revealed a remarkable prevalence among healthy weight individuals, leading investigations into the genetic, lifestyle, and dietary factors that contribute to the development of MAFLD in this population. This shift in perspective requires reconsideration of preventive strategies, diagnostic criteria and therapeutic approaches tailored to address the unique characteristics of MAFLD healthy weight individuals. It also underscores the importance of widespread awareness and education, within the medical community and among the general population, to promote a more inclusive understanding of liver metabolic disorders. With this review, we aim to provide a comprehensive exploration of MAFLD in healthy weight individuals, encompassing epidemiological, pathophysiological, and clinical aspects.
代谢相关脂肪性肝病（MAFLD）是一个日益严重的公共卫生问题，影响了全球三分之一的人口。与传统观念相反，MAFLD 不仅局限于肥胖或超重人群。流行病学研究表明，在健康体重人群中，MAFLD 的患病率也相当高，这促使人们深入研究导致这部分人群发生 MAFLD 的遗传、生活方式和饮食因素。这种观点的转变需要重新考虑针对 MAFLD 健康体重个体的预防策略、诊断标准和治疗方法。它还强调了在医疗界和普通人群中广泛宣传和教育的重要性，以促进对肝脏代谢紊乱的更全面的理解。通过这篇综述，我们旨在全面探讨 MAFLD 在健康体重个体中的表现，包括流行病学、病理生理学和临床方面。
